UK pharmaceutical powerhouse AstraZeneca is reportedly in discussions with its American rival, Bristol Myers Squibb, regarding a colossal merger that could create a combined entity valued at an astonishing $400 billion. This potential megadeal, initially brought to light by the Financial Times on Sunday, would mark one of the largest corporate mergers in history.
While the definitive outcome of these negotiations remains uncertain, sources close to the matter informed the FT that talks have been ongoing for several months, indicating serious consideration by both parties.
Bristol Myers Squibb has cultivated a robust presence in the cancer treatment sector through a strategic acquisition spree, acquiring seven companies since October 2007. Notable among these was the July purchase of Medarex, which brought a crucial drug for metastatic melanoma into its portfolio, currently in Phase III trials. This drug also shows promise for treating lung and prostate cancers. The company's oncology arsenal further includes established treatments like Erbitux for colorectal, head, and neck cancers, Ixempra for breast cancer, and Taxol.
Neither AstraZeneca (AZN) nor Bristol Myers Squibb (BMY) immediately responded to a request for comment from CNBC regarding the reported discussions.
Last year, AstraZeneca had signaled its intent for a direct U.S. stock market listing, aiming to leverage the often-higher valuations available in the American market while maintaining its primary listing in London. Under the 14-year leadership of CEO Pascal Soriot, AstraZeneca's share price has more than quadrupled, significantly outperforming the broader FTSE 100 index and its key British competitor, GSK.
The timing of this potential deal follows AstraZeneca's recent second-quarter results, which showcased continued strong demand for its cancer and rare disease medications. In 2025, cancer treatments alone are projected to account for approximately $25 billion in sales, representing nearly half of the company’s total revenue, with cardiovascular, renal, and metabolism treatments contributing around $12 billion.
Interestingly, this news surfaces approximately 12 years after AstraZeneca successfully thwarted a takeover attempt by its larger U.S. rival, Pfizer (PFE).
For a detailed account, you can read the complete Financial Times story here.
▶
WATCH: AstraZeneca CFO: Very confident we will hit $80 billion revenue target (8:56)
— Reuters contributed to this report.
